Free Trial

Novartis (NVS) Stock Forecast & Price Target

Novartis logo
$118.53 +0.51 (+0.44%)
As of 11:02 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
6
Buy
2

Based on 11 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 3 have given a sell rating, 6 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for NVS.

Consensus Price Target

$123.38
4.08% Upside
According to the 11 analysts' twelve-month price targets for Novartis, the average price target is $123.38. The highest price target for NVS is $130.00, while the lowest price target for NVS is $120.00. The average price target represents a forecasted upside of 4.08% from the current price of $118.53.
Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

Sign Up

NVS Analyst Ratings Over Time

TypeCurrent Forecast
6/10/24 to 6/10/25
1 Month Ago
5/11/24 to 5/11/25
3 Months Ago
3/12/24 to 3/12/25
1 Year Ago
6/11/23 to 6/10/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$123.38$123.38$123.38$116.67
Forecasted Upside4.08% Upside13.52% Upside13.43% Upside10.71% Upside
Consensus Rating
Hold
Hold
Reduce
Hold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside4.55% Upside5,918.89% Upside13.46% Upside
News Sentiment Rating
Positive News

See Recent NVS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2025BNP Paribas
4 of 5 stars
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/13/2025UBS Group
3 of 5 stars
Matthew Weston
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
2/12/2025Morgan Stanley
3 of 5 stars
 Initiated CoverageUnderweight
2/4/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
2/3/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweight ➝ Underweight
12/4/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Reduce
11/19/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
10/30/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$118.00 ➝ $120.00+8.53%
9/11/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$135.00 ➝ $130.00+11.08%
9/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Quigley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$119.00 ➝ $121.00+1.37%
9/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:02 AM ET.


Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 9, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Novartis AG:

  • The current stock price is around $116, which is relatively stable and shows potential for growth given the average price target of $123.38.
  • Novartis AG reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.28, exceeding analyst expectations, indicating robust financial health.
  • The company has demonstrated significant revenue growth, with a year-over-year increase of 11.9%, suggesting effective business strategies and product demand.
  • With a return on equity of 37.24%, Novartis AG shows efficient use of shareholders' equity to generate profits, which is attractive to investors looking for strong returns.
  • The firm maintains a low debt-to-equity ratio of 0.48, indicating a conservative approach to leveraging, which can reduce financial risk for investors.

Novartis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Novartis AG for these reasons:

  • The stock has a consensus rating of "Hold," which may suggest that analysts are not overly optimistic about its short-term performance.
  • Despite recent revenue growth, the company faces competitive pressures in the pharmaceutical industry, which could impact future earnings.
  • Novartis AG has a relatively low beta of 0.60, indicating less volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • The current ratio of 1.04 is just above 1, suggesting that while the company can cover its short-term liabilities, it may not have a strong buffer for unexpected expenses.
  • Market conditions and regulatory changes in the healthcare sector could pose risks to Novartis AG's operations and profitability, making it a cautious investment choice.

NVS Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $123.38, with a high forecast of $130.00 and a low forecast of $120.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 3 sell ratings, 6 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted upside of 4.08% based on their 12-month stock forecasts.

Over the previous 90 days, Novartis's stock had 1 upgrade by analysts.

Novartis has been rated by research analysts at BNP Paribas in the past 90 days.

Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.


This page (NYSE:NVS) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners